The only VMAT2 inhibitor indicated for tardive dyskinesia (TD) with no recommendations against concomitant use with strong CYP3A4/5 inducers or inhibitors1

Consider AUSTEDO for patients with TD receiving strong CYP3A4/5 inducers or inhibitors for underlying conditions

  • AUSTEDO is metabolized primarily through CYP2D6—with minor contributions of CYP3A4/5 and other enzymes to form several minor metabolites

Coadministration per pathway dosing for AUSTEDO and INGREZZA® (valbenazine).

Coadministration per pathway dosing for AUSTEDO and INGREZZA® (valbenazine).

  • In patients who are poor CYP2D6 metabolizers or are taking strong CYP2D6 inhibitors, the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg)1
Concomitant medication pills icon.

For patients on concomitant medications, AUSTEDO offers a range of dosing options1

  • In the treatment of TD, it is important to keep in mind how concomitant drugs for comorbid conditions are metabolized1-3
  • For a list of medications that can help determine potential drug-drug interactions with your patients’ concomitant treatments, see the Flockhart™ Table

Consider metabolic pathways when choosing a treatment for TD1-3

TD Talks Logo.

Watch Dr.
Rakesh Jain discuss drug metabolism as a crucial consideration for TD treatment

VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. INGREZZA® (valbenazine) current Prescribing Information. San Diego, CA: Neurocrine Biosciences, Inc.; April 2020. 3. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Academy of Family Physicians. 2007;76(3):391-396.